With the progressive decline in mortality rates in intensive care units in recent decades, increasing attention has been drawn to the fact that many patients who survive their stay in the intensive care unit develop long-lasting physical, cognitive and psychological impairments, which can last for months or even years after their critical illness. This health problem, known as post-intensive care syndrome, can be alleviated by implementing certain practices during hospitalisation, and its treatment generally requires attention upon discharge from hospital. The stress and trauma associated with the intensive care unit experience can also affect family members in the long term, manifesting as mental health problems known as family post-intensive care syndrome. In this context, pharmacists play a key role in the prevention and treatment of post-intensive care syndrome, integrating into multidisciplinary teams in both the intensive care unit and post-intensive care unit recovery clinics. Their intervention includes comprehensive optimisation of pharmacotherapy, reconciliation, identification and prevention of adverse drug events, and health education for patients and their families.
10 February 2026 in Anales del Sistema Sanitario de Navarra
Introducción. La pauta habitual de linezolid se asocia con exposición subóptima en pacientes críticos. En este estudio se analiza la asociación entre las distintas modalidades de tratamiento (dosis, tiempo de infusión) y la probabilidad de alcanzar los objetivos farmacocinéticos/farmacodinámicos, evaluando su impacto microbiológico y clínico. Pacientes y métodos. Estudio retrospectivo en pacientes ingresados en unidades de cuidados intensivos con monitorización terapéutica de linezolid entre mayo de 2021 y diciembre de 2023. Se analizó el cumplimiento de los objetivos farmacocinéticos/farmacodinámicos (Cmin: 2-7 mg/L, AUC: 0–24/CMI: 80–120 mg*h/L, y T>CMI ≥85%) en función de la pauta inicial (1.200 o 1.800 mg/día) y tiempo de infusión (1 o 3 h). Se analizaron subgrupos de riesgo: obesidad, aclaramiento de creatinina aumentado, técnicas de reemplazo renal y <65años Resultados. Se incluyeron 70 pacientes. En la primera monitorización, el 18,6% alcanzó los tres objetivos farmacocinéticos/farmacodinámicos y el 40% tuvo la Cmin en rango. No hubo diferencias estadísticamente significativas en la consecución de objetivos según la pauta o el tiempo de infusión (tampoco en subgrupos de riesgo). Sin embargo, el cumplimiento de Cmin fue superior con la dosis de 1.800 mg/día (54,5% vs. 37,3%). Tampoco se detectaron diferencias significativas respecto a resultados microbiológicos y clínicos según Cmin estuviese en rango o no. Conclusiones. Menos del 20% de pacientes alcanzó todos los objetivos farmacocinéticos/farmacodinámicos con la pauta inicial. Estos resultados sugieren la necesidad de individualizar y monitorizar las pautas para optimizar el tratamiento en esta población, especialmente en perfiles de riesgo.
1 January 2026 in Emergency Medicine International
Introduction: Albumin, the most abundant blood protein, is widely used as a plasma expander in critically ill patients. Objective: To evaluate the efficacy and safety of albumin compared to other alternatives in the prevention and treatment of complications in critically ill adults, considering different comparators and clinical situations. Methods: A systematic review was conducted, including randomized controlled trials (RCTs) comparing albumin with crystalloids, other colloids, or standard care without albumin. Primary outcomes were total mortality, blood transfusion requirement, and serious adverse events. The search was performed in MEDLINE, Embase, and Cochrane Central. Meta‐analysis was conducted using the Mantel–Haenszel method with a random‐effects model, and heterogeneity was assessed with the I 2 statistic. The risk of bias was evaluated using Cochrane RevMan 5.4, and the quality of evidence was assessed with the GRADE approach. Results: Thirty‐five RCTs involving 13,975 critically ill adults were included. Mortality was 23.8% (1327/5586) with albumin and 24.2% (1361/5618). Compared with colloids, mortality was 21.9% (83/379) versus 24.4% (113/463). When compared with standard care without albumin, mortality was higher with albumin: 15.8% (60/380) versus 9.2% (39/424). SAEs occurred in 37.6% (298/793) of albumin‐treated patients versus 33.5% (266/793) with crystalloids. Albumin required less transfused blood volume than colloids. Conclusions: Albumin showed no benefit over crystalloids, colloids, or standard care without albumin in reducing mortality. It resulted in less blood transfusions compared to colloids, but serious adverse events were higher than with crystalloids.
With the progressive decline in mortality rates in intensive care units in recent decades, increasing attention has been drawn to the fact that many patients who survive their stay in the intensive care unit develop long-lasting physical, cognitive and psychological impairments, which can last for months or even years after their critical illness. This health problem, known as post-intensive care syndrome, can be alleviated by implementing certain practices during hospitalisation, and its treatment generally requires attention upon discharge from hospital. The stress and trauma associated with the intensive care unit experience can also affect family members in the long term, manifesting as mental health problems known as family post-intensive care syndrome. In this context, pharmacists play a key role in the prevention and treatment of post-intensive care syndrome, integrating into multidisciplinary teams in both the intensive care unit and post-intensive care unit recovery clinics. Their intervention includes comprehensive optimisation of pharmacotherapy, reconciliation, identification and prevention of adverse drug events, and health education for patients and their families.